Novel vitamin D3 analog (CB 1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo

International Journal of Oncology

Volumn 13, Issue 3, 1998, Pages 421-428

  Koshizuka, Kozo ^a   Koike, Michiaki ^a   Kubota, Tetsuya ^a   Said, Jonathan ^a   Binderup, Lise ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEO PHARMA A S   (Denmark)

Author keywords

BNX mice; Breast cancer; Cisplatin; Paclitaxel; Vitamin D3 analog

Indexed keywords

1,3 DIHYDROXY 20 (1 ETHOXY 5 ETHYL 5 HYDROXY 2 HEPTYN 1 YL) 9,10 SECOPREGNA 5,7,10 TRIENE 1,25 DIHYDROXYVITAMIN D3; 20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; CALCITRIOL; CISPLATIN; COLECALCIFEROL DERIVATIVE; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; BREAST TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DRUG EFFECT; KIDNEY; LIVER; MOUSE STRAIN; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CALCITRIOL; CELL DIVISION; CISPLATIN; FEMALE; HUMANS; KIDNEY; LIVER; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031595508     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.3.421     Document Type: Article

References (24)

1. De Lena M, Brambilla C, Morabito A and Bonadonna G: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35: 1108-1115, 1975.
2. Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, Blom J, Perlin E and Simon R: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649-1657, 1978.
3. Walters MR: Newly identified actions of vitamin D endocrine system. Endocr Rev 13: 719-764, 1992.
4. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW and Coombes RC: Immunocytochemical detection of 1,25 dihydroxyvitamin D receptors in breast cancer. Cancer Res 47: 6793-6799, 1987.
5. 3. Clin Endocrinol 13: 267-272, 1980.
6. Frealce H, Abayasakera G, Iwasaki J, Marcocci C, Maclntyre I, McClelland R, Skilton R, Easton D and Coombes RC: Measurement of 1,25-dihydroxy vitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res 44: 1677-1681, 1987.
7. Eisman J, Suva L, Sher E, Pierce P, Funder J and Martin TJ: 1,25-dihydroxyvitamin D3 receptor in human breast cancer. Cancer Res 41: 5121-5124, 1981.
8. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55: 2822-2830, 1995.
9. Colston KW, Berger U and Coombes RC: Possible role for vitamin D in controlling breast cancer cells proliferation. Lancet 28: 188-191, 1989.
10. Colston KW, Chander SK, Mackay AG and Coombes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44: 693-702, 1992.
11. Danielpour D, Kadomatsu K, Anzano MA, Smith JM and Sporn MB: Development and characterization of non-tumorigeniec and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 54: 3413-3421, 1994.
12. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT and Coombes RC: Topical calcipotriol treatment in advanced breast cancer. Lancet 337: 701-702, 1991.
13. Abe J, Nakano T, Nishi Y, Matsumoto T, Ogata E and Ikeda K: A novel vitamin D3 analog, 22-Oxa-1.25-dihydroxy vitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129: 832-837, 1991.
14. 3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood 84: 1960-1968, 1994.
15. Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M and Koeffler HP: 20-epi-vitamin D3 analogs: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55: 2822-2830, 1995.
16. Imai Y, Pike JW and Koeffler HP: Potent vitamin D3 analogs: their abilities to enhance transactivation and to bind the vitamin D3 response element. Leukemia Res 19: 147-158, 1995.
17. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 87: 3929-3932, 1990.
18. 3 analogs and 9-cis retinoic acid. J Clin Invest 99: 1-12, 1997.
19. DeVos S, Dawson MI, Holden S, Le T, Wang A, Cho SK; Chen D-L and Koeffler HP: Effects of novel, potent Retinoic X Receptor (RXR) specific ligands and ligands with anti-AP-1 activity on proliferation of prostate cancer cells. Prostate (In press).
20. Hansen CM, Danielsson C and Carlberg C: The potent anti-proliferative effect of 20-epi analogues of 1,25 dihydroxyvitamin D3 in human breast-cancer MCF-7 cells is related to promoter selectivity. Int J Cancer 67: 739-742, 1995.
21. 3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of VDR-RXR heterodimer-mediated transactivation. Mol Cell Biol 15: L1154-L1161, 1995.
22. Carlberg C, Mathiasen YS, Saurat Y-H and Binderup L: The 1,25-dihydroxyvitamin D3 (VD) analog MC903, EB1089 and KH1060 activate the VD receptor: homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors. J Steroid Biochem Mol Biol 51: 137-142, 1994.
23. Peleg S, Sastry M, Collinst E, Bishop YE and Norman AW: Distinct conformational changes induced by 20-epi analogs of 1α,25-dihydroxyvitamin D3 are assicated with enhanced activation of the vitamin D receptor. J Biol Chem 270: 3-8, 1995.
24. Schräder M, Müller KM and Carlberg C: Specificity and flexibility of vitamin D signaling. J Biol Chem 269: 5501-5505, 1994.